| Patent application number | Description | Published |
|---|
| 20080213247 | Mbms as Modifiers of Branching Morphogenesis and Methods of Use - Human MBM genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of MBM are provided. | 09-04-2008 |
| 20080241131 | SPHKS as modifiers of the p53 pathway and methods of use - Human SPHK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SPHK are provided. | 10-02-2008 |
| 20080317738 | Mylks as Modifiers of Branching Morphogenesis and Methods of Use - Human MYLK genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of MYLK are provided. | 12-25-2008 |
| 20090068186 | MAP3Ks as modifiers of the p53 pathway and methods of use - Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided. | 03-12-2009 |
| 20090098112 | NOVEL ANTIBODIES - The present invention relates to the use of VEGF antagonists and a novel anti-α5β1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-α5β1 antibodies and methods of making and using them. | 04-16-2009 |
| 20090220504 | COMBINATORIAL THERAPY - The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them. | 09-03-2009 |
| 20100159470 | SCDs As Modifiers of the p53 Pathway and Methods of Use - Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided. | 06-24-2010 |
| 20100260782 | NOVEL ANTI- Alpha 5 Beta 1 ANTIBODIES AND USES THEREOF - The present invention provides new anti-α5β1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies. | 10-14-2010 |
| 20100275275 | HADHs as Modifiers of the p21 Pathway and Methods of Use - Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided. | 10-28-2010 |
| 20100325743 | Marks as modifiers of the p53 pathway and methods of use - Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided. | 12-23-2010 |
| 20110159508 | GFATS as Modifiers of the P53 Pathway and Methods of Use - Human GFAT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of GFAT are provided. | 06-30-2011 |
